Open-Label Trial of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Filgrastim in Normal Donors

Amgen

Status: Completed

Conditions: Normal PBPC Donors

Treatments: Drug: filgrastim

Study type: Observational

Funder types: Industry

Identifiers

NCT00115128

20020143

Details and patient eligibility

About

The purpose of this study is to clinically evaluate the spleen during PBPC mobilization by filgrastim in normal donors.

Enrollment: 309 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria: - Eligible to be PBPC donor for allogeneic transplantation as determined by local institution Exclusion Criteria: - History of splenectomy - Previous PBPC mobilization attempts - Previous treatment with GCSF or GMCSF

Trial design

309 participants in 1 patient group

Filgrastim

Description:

Normal donors being treated with filgrastim for PBPC mobilization and collection

Treatment:

Drug: filgrastim